URGN 8-K 2026-11-04
UroGen Pharma Ltd. (URGN) 8-K dated 2026-11-04 — accession 0001437749-26-034769.
UroGen Pharma Ltd. (URGN) is a biotechnology company listed on NASDAQ.
URGN revenue $89M
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported URGN revenue for 2025-12-31 was $109.8M. Net income was -$153.5M. Revenue was up 21.4% from 2024-12-31 to 2025-12-31. URGN currently screens at market cap $1.61B.
Not investment advice. The URGN SEC hub lists recent forms. The stock page is the research view.
- Revenue
- $89M
- Guidance
- full-year 2026 net product revenue guidance for JELMYTO to approximately $90 million, compared with its prior guidance range of $
Why it matters
- full-year 2026 net product revenue guidance for JELMYTO to approximately $90 million, compared with its prior guidance range of $